Keyphrases
Immune Checkpoint Inhibitors
77%
Rheumatoid Arthritis
70%
Cancer Therapy
52%
Inflammatory Arthritis
39%
Disease-modifying Antirheumatic Drugs (DMARDs)
35%
Confidence Interval
27%
Immune-related Adverse Events
27%
Adverse Events
24%
Risk Ratio
20%
Comprehensive Cancer Center
19%
Melanoma
19%
Arthritis
19%
Smoking Abstinence
17%
Adalimumab
17%
Antiphospholipid Antibodies
17%
Patient Needs
17%
Jordan
17%
Refractory Myositis
17%
Adjuvant Therapy
17%
Research Training
17%
Training Program
17%
Abstinence Rate
17%
Baricitinib
17%
Genetic Determinants
17%
Febuxostat
17%
Chronic Gout
17%
Hematopoietic Cell Transplantation
17%
Funding Information
17%
Adverse Events Profile
17%
Immune Checkpoint Blockade
17%
Myositis
17%
Learning Needs
17%
Patients with Cancer
17%
Leflunomide
17%
Salvage Therapy
17%
Anti-interleukin-6 Receptor
17%
Solid Tumors
17%
Pre-existing Autoimmune Disease
17%
Acute Limb Ischemia
17%
Overall Survival
17%
Solid Malignancies
17%
Biologic Disease-modifying Antirheumatic Drugs
17%
Bupropion
17%
Varenicline
17%
Antirheumatic Drugs
17%
Sustained Release
17%
Multi-inflammatory Syndrome
17%
Cytomegalovirus Infection
17%
Cancer Diagnosis
14%
Smokers
14%
Medicine and Dentistry
Immune Checkpoint Inhibitor
64%
Malignant Neoplasm
63%
Rheumatoid Arthritis
46%
Inflammatory Arthritis
46%
Biological Product
39%
Arthritis
36%
Tocilizumab
35%
Myositis
35%
Cancer
34%
Antirheumatic Agent
31%
Immune-Related Adverse Events
24%
Immunity
23%
Adverse Event
23%
Overall Survival
22%
TNF Inhibitor
19%
Cancer Therapy
19%
Adjuvant Therapy
17%
Salvage Therapy
17%
Interstitial Nephritis
17%
Cell Transplantation
17%
Hematopoietic Cell
17%
Critical Limb Ischemia
17%
Nephrotoxicity
17%
Disease Modifying Antirheumatic Drug
17%
T Cell Receptor
17%
Cytomegalovirus Infection
17%
Leflunomide
17%
Immune Checkpoint Blockade
17%
T Cell
17%
Autoimmune Disease
17%
Pseudogout
17%
Diseases
17%
Cholangiocarcinoma
17%
Acute Kidney Injury
14%
Cytomegalovirus
13%
Effector Cell
12%
Cancer Diagnosis
11%
Exon
11%
Renal Biopsy
10%
Glomerulonephritis
10%
Biopsy Technique
10%
Toxicity and Intoxication
10%
Cytokine Release Syndrome
10%
Cell Therapy
10%
Hazard Ratio
9%
Hematopoietic Stem Cell Transplantation
8%
Receptor Antibody
8%
Interleukin 6 Receptor
8%
Immunosuppressive Treatment
7%
Melanoma
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Rheumatoid Arthritis
78%
Inflammatory Arthritis
78%
Adverse Event
67%
Immune Checkpoint Inhibitor
46%
Biological Product
39%
Myositis
35%
Antirheumatic Agent
26%
Observational Study
21%
Diseases
21%
Overall Survival
21%
Tumor Necrosis Factor Inhibitor
18%
Arthritis
18%
Pseudogout
17%
Cytomegalovirus Infection
17%
Leflunomide
17%
Critical Limb Ischemia
17%
Febuxostat
17%
Baricitinib
17%
Sustained Release
17%
Disease Modifying Antirheumatic Drug
17%
Tocilizumab
17%
Solid Malignant Neoplasm
17%
Antiphospholipid Antibody
17%
Varenicline
17%
Bupropion
17%
Adalimumab
17%
Bile Duct Carcinoma
17%
Lung Cancer
15%
Cytomegalovirus
13%
Thromboembolism
10%
Tumor Necrosis Factor
8%
Receptor Antibody
8%
Interleukin 6 Receptor
8%
Melanoma
7%
Urogenital Tract Cancer
7%
Digestive System Cancer
7%
Polyarthritis
6%
Survival Rate
6%
Side Effect
6%
Clinical Trial
5%
Biliary Tract Cancer
5%
Mitogen Activated Protein Kinase
5%
Immunoglobulin
5%
Vemurafenib
5%
Nicotine Replacement Therapy
5%
Prevalence
5%
Calcium Pyrophosphate
5%
